Consortium of Early Arthritis Cohorts USA

Terminated

• Conditions: Rheumatoid Arthritis

• Registration Number: NCT02386527
• Lead Sponsor: Hospital for Special Surgery, New York

Brief Summary

Rheumatoid arthritis (RA) is the most common form of inflammatory arthritis. In the US, it is estimated that as many as 3 million adults may suffer from the disease. Fortunately in the last few years, a shift in strategy toward the earlier institution of disease modifying drugs and the availability of new classes of medications have greatly improved the outcomes that can be expected by most patients.

The goal of treatment now aims toward achieving the lowest possible level of arthritis disease activity and even remission, if possible as early on as possible. Research has shown that this translates into minimized joint damage and enhanced physical function and quality of life for the RA patient. This also requires that a diagnosis of RA be made as early on as possible, and herein lies the challenge, i.e. identifying the RA patient early on in the course of their disease.

Detailed Description

This is a study of usual care, a prospective cohort of all eligible and consenting patients referred to the Inflammatory Arthritis Center of Excellence and the Division of Rheumatology, Department of Medicine at HSS as well as 3 consortium sites across the U.S.

In order to study the effectiveness of recommended treatments in usual practice in different patients for short-term and long-term outcomes, and to determine factors that may predict how a patient's disease might progress over time, investigators will need to analyze and describe the strategies used to manage these patients and will need to understand:

i. The frequency of single time-point and sustained (two or more time points) remission or low disease activity over time ii. Factors that influence remission iii. Which patients can achieve persistent sustained remission, and iv. Who can undergo drug withdrawal and still sustain remission of low disease activity v. Factors associated with treatment optimization or barriers to achieving this

Study Timeline

• Study Start: 2014-12-01
• Study First Submitted: 2015-02-26
• Study First Submitted QC: 2015-03-06
• Study First Posted: 2015-03-12
• Primary Completion: 2024-04
• Study Completion: 2024-04
• Status Verified: 2024-11
• Last Update Submitted: 2025-04-10
• Last Update Posted: 2025-04-13

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 119

Inclusion Criteria

• Patient was 18 years of age or over at time of referral
• Joint symptoms for < 12 months
• 2+ swollen joints OR 1 swollen joint with one of the following: Rheumatoid Factor > 20 IU, (+) anti-CCP antibody, morning stiffness > 45 minutes, responded to NSAIDs, (+) MTP squeeze test

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Rapidity and sustainability of SDAI remission as achieved over a one year period	3 months, 6 months, 9 months and 12 months of follow-up

Secondary Outcome Measures

Name	Time	Method
The proportion of patients achieving DAS28 remission and CDAI remission twice	3 months, 6 months, 9 months and 12 months of follow-up
Rapid radiographic progression, as measured by a van der Heijde Sharp Score change of 5 point or more	2 months and 24 months of follow-up

Trial Locations

Locations (1)

Hospital for Special Surgery; 🇺🇸 New York, New York, United States